AAAAAA

   
Results: 1-25 | 26-47
Results: 1-25/47
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families
Authors: Verhoog, LC van den Ouweland, AMW Berns, E van Veghel-Plandsoen, MM van Staveren, IL Wagner, A Bartels, CCM Tilanus-Linthorst, MMA Devilee, P Seynaeve, C Halley, DJJ Niermeijer, MF Klijn, JGM Meijers-Heijboer, H
Citation: Lc. Verhoog et al., Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families, EUR J CANC, 37(16), 2001, pp. 2082-2090
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk
Authors: Brekelmans, CTM Seynaeve, C Bartels, CCM Tilanus-Linthorst, MMA Meijers-Heijboer, EJ Crepin, CMG van Geel, AN Menke, M Verhoog, LC van den Ouweland, A Obdeijn, IM Klijn, JGM
Citation: Ctm. Brekelmans et al., Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk, J CL ONCOL, 19(4), 2001, pp. 924-930
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
Authors: Klijn, JGM Blamey, RW Boccardo, F Tominaga, T Duchateau, L Sylvester, R
Citation: Jgm. Klijn et al., Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials, J CL ONCOL, 19(2), 2001, pp. 343-353
Clinical relevance of biologic factors in male breast cancer
Authors: Meijer-van Gelder, ME Look, MP Bolt-de Vries, J Peters, HA Klijn, JGM Foekens, JA
Citation: Me. Meijer-van Gelder et al., Clinical relevance of biologic factors in male breast cancer, BREAST CANC, 68(3), 2001, pp. 249-260
Psychological impact of receiving a BRCA1/BRCA2 test result
Authors: Lodder, L Frets, PG Trijsburg, RW Meijers-Heijboer, EJ Klijn, JGM Duivenvoorden, HJ Tibben, A Wagner, A van der Meer, CA van den Ouweland, AMW Niermeijer, MF
Citation: L. Lodder et al., Psychological impact of receiving a BRCA1/BRCA2 test result, AM J MED G, 98(1), 2001, pp. 15-24
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
Authors: Meijers-Heijboer, H van Geel, B van Putten, WLJ Henzen-Logmans, SC Seynaeve, C Menke-Pluymers, MBE Bartels, CCM Verhoog, LC van den Ouweland, AMW Niermeijer, MF Brekelmans, CTM Klijn, JGM
Citation: H. Meijers-heijboer et al., Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation., N ENG J MED, 345(3), 2001, pp. 159-164
Prophylactic mastectomy in carriers of BRCA mutations - Reply
Authors: Klijn, JGM Meijers-Heijboer, H
Citation: Jgm. Klijn et H. Meijers-heijboer, Prophylactic mastectomy in carriers of BRCA mutations - Reply, N ENG J MED, 345(20), 2001, pp. 1499-1500
Tamoxifen resistance in breast cancer - Elucidating mechanisms
Authors: Dorssers, LCJ van der Flier, S Brinkman, A van Agthoven, T Veldscholte, J Berns, EMJJ Klijn, JGM Beex, LVAM Foekens, JA
Citation: Lcj. Dorssers et al., Tamoxifen resistance in breast cancer - Elucidating mechanisms, DRUGS, 61(12), 2001, pp. 1721-1733
Thymidine kinase and thymidylate synthase in advanced breast cancer: Response to tamoxifen and chemotherapy
Authors: Foekens, JA Romain, S Look, MP Martin, PM Klijn, JGM
Citation: Ja. Foekens et al., Thymidine kinase and thymidylate synthase in advanced breast cancer: Response to tamoxifen and chemotherapy, CANCER RES, 61(4), 2001, pp. 1421-1425
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer
Authors: Foekens, JA Peters, HA Grebenchtchikov, N Look, MP Meijer-van Gelder, ME Geurts-Moespot, A van der Kwast, TH Sweep, CGJ Klijn, JGM
Citation: Ja. Foekens et al., High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer, CANCER RES, 61(14), 2001, pp. 5407-5414
Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling
Authors: van de Wetering, M Barker, N Harkes, IC van der Heyden, M Dijk, NJ Hollestelle, A Klijn, JGM Clevers, H Schutte, M
Citation: M. Van De Wetering et al., Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling, CANCER RES, 61(1), 2001, pp. 278-284
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2
Authors: Schuyer, M van der Burg, MEL Henzen-Logmans, SC Fieret, JH Klijn, JGM Look, MP Foekens, JA Stoter, G Berns, EMJJ
Citation: M. Schuyer et al., Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2, BR J CANC, 85(9), 2001, pp. 1359-1367
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features
Authors: Berns, EMJJ van Staveren, IL Verhoog, L van de Ouweland, AMW Meijer-van Gelder, M Meijers-Heijboer, H Portengen, H Foekens, JA Dorssers, LCJ Klijn, JGM
Citation: Emjj. Berns et al., Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features, BR J CANC, 85(4), 2001, pp. 538-545
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex (TM) and Tamoxifen Alone or in Combination' (ATAC) trial
Authors: Baum, M Dowsett, M Coibion, M Bianco, AR Cuzick, J George, WD Gray, J Howell, A Houghton, J Williams, N Sloane, J Tobias, J Buzdar, A Anderson, MD Jackson, I Sahmoud, T Gallagher, J Webster, A Gangji, D Petrakova, K Konopasek, B Mares, P Vodvarka, P Alcazar, A Campos, O Maxwell, A",Goedhals,"Hacking, D Landers, G Smith, L Vorobiof, DA Werner, ID Blamey, R Coleman, R Grieve, RJ Hickish, T Howell, A Nicholls, JC Nicholson, S Raymond, S Salman, A Blum, J Clark, R Lyss, A Miletello, G Sternberg, J Forbes, J Coibion, M Nabholtz, JM Guastalla, JP Distler, W Klijn, JGM Nagykalnai, T Nicolucci, A Bianco, AR Constenla, M Nylen, U Howell, A Sainsbury, R Mansel, RE Goerge, D Buzdar, AU Locker, GY Gallagher, J Jackson, I Sahmoud, T Houghton, J Williams, N Nicolucci, A Pollard, S Stroner, P Buyse, M Margolese, R Northover, JMA
Citation: M. Baum et al., Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex (TM) and Tamoxifen Alone or in Combination' (ATAC) trial, BR J CANC, 85(3), 2001, pp. 317-324
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
Authors: de Witte, JH Foekens, JA Brunner, N Heuvel, JJTM van Tienoven, TH Look, MP Klijn, JGM Geurts-Moespot, A Grebenchtchikov, N Benraad, TJ Sweep, CGJ
Citation: Jh. De Witte et al., Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours, BR J CANC, 85(1), 2001, pp. 85-92
Re: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study - Response
Authors: Klijn, JGM Duchateau, L
Citation: Jgm. Klijn et L. Duchateau, Re: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study - Response, J NAT CANC, 92(24), 2000, pp. 2041-2042
Bcar1/p130Cas protein and primary breast cancer: Prognosis and response totamoxifen treatment
Authors: van der Flier, S Brinkman, A Look, MP Kok, EM Meijer-van Gelder, ME Klijn, JGM Dorssers, LCJ Foekens, JA
Citation: S. Van Der Flier et al., Bcar1/p130Cas protein and primary breast cancer: Prognosis and response totamoxifen treatment, J NAT CANC, 92(2), 2000, pp. 120-127
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
Authors: Klijn, JGM Beex, LVAM Mauriac, L van Zijl, JA Veyret, C Wildiers, J Jassem, J Piccart, M Burghouts, J Becquart, D Seynaeve, C Mignolet, F Duchateau, L
Citation: Jgm. Klijn et al., Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study, J NAT CANC, 92(11), 2000, pp. 903-911
The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2
Authors: Lakhani, SR Gusterson, BA Jacquemier, J Sloane, JP Anderson, TJ van de Vijver, MJ Venter, D Freeman, A Antoniou, A McGuffog, L Smyth, E Steel, CM Haites, N Scott, RJ Goldgar, D Neuhausen, S Daly, PA Ormiston, W McManus, R Scherneck, S Ponder, BAJ Futreal, PA Peto, J Stoppa-Lyonnet, D Bignon, YJ Struewing, JP Bishop, DT Klijn, JGM Devilee, P Cornelisse, CJ Lasset, C Lenoir, G Barkardottir, RB Egilsson, V Hamann, U Chang-Claude, J Sobol, H Weber, B Easton, DF Stratton, MR
Citation: Sr. Lakhani et al., The pathology of familial breast cancer: Histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2, CLIN CANC R, 6(3), 2000, pp. 782-789
Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist
Authors: Kramer, JA Curran, D Piccart, M de Haes, JCJM Bruning, PF Klijn, JGM Bontenbal, M van Pottelsberghe, C Groenvold, M Paridaens, R
Citation: Ja. Kramer et al., Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam Symptom Checklist, EUR J CANC, 36(12), 2000, pp. 1488-1497
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European organization for research and treatment of cancer randomized study with cross-over
Authors: Paridaens, R Biganzoli, L Bruning, P Klijn, JGM Gamucci, T Houston, S Coleman, R Schachter, J Van Vreckem, A Sylvester, R Awada, A Wildiers, J Piccart, M
Citation: R. Paridaens et al., Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European organization for research and treatment of cancer randomized study with cross-over, J CL ONCOL, 18(4), 2000, pp. 724-733
Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer
Authors: Bontenbal, M van Putten, WLJ Burghouts, JTM Baggen, MGA Ras, GJ Stiegelis, WF Beudeker, M Janssen, JTP Braun, JJ van der Linden, GHM van der Velden, PC van Geel, AN Helle, P Leisink, M Foekens, JA Klijn, JGM
Citation: M. Bontenbal et al., Value of estrogenic recruitment before chemotherapy: First randomized trial in primary breast cancer, J CL ONCOL, 18(4), 2000, pp. 734-742
Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients
Authors: Verhoog, LC Berns, EMJJ Brekelmans, CTM Seynaeve, C Meijers-Heijboer, EJ Klijn, JGM
Citation: Lc. Verhoog et al., Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients, J CL ONCOL, 18(21), 2000, pp. 119S-124S
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation
Authors: Meijers-Heijboer, EJ Verhoog, LC Brekelmans, CTM Seynaeve, C Tilanus-Linthorst, MMA Wagner, A Dukel, L Devilee, P van den Ouweland, AMW van Geel, AN Klijn, JGM
Citation: Ej. Meijers-heijboer et al., Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation, LANCET, 355(9220), 2000, pp. 2015-2020
Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer
Authors: Klijn, JGM Setyono-Han, B Foekens, JA
Citation: Jgm. Klijn et al., Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer, STEROIDS, 65(10-11), 2000, pp. 825-830
Risultati: 1-25 | 26-47